Stock News

IntriCon (IIN) Reaches $44.10 52-Week High; 7 Analysts Covering Hikma Pharmaceuticals PLC (LON:HIK)

Hikma Pharmaceuticals PLC (LON:HIK) Logo

Among 15 analysts covering Hikma Pharmaceuticals PLC (LON:HIK), 7 have Buy rating, 2 Sell and 6 Hold. Therefore 47% are positive. Hikma Pharmaceuticals PLC had 181 analyst reports since July 29, 2015 according to SRatingsIntel. AlphaValue maintained the stock with “Reduce” rating in Thursday, August 6 report. Jefferies maintained Hikma Pharmaceuticals PLC (LON:HIK) on Wednesday, March 16 with “Buy” rating. Goldman Sachs maintained it with “Buy” rating and GBX 2840 target in Friday, September 4 report. The firm has “Buy” rating given on Monday, April 11 by Citigroup. The firm earned “Buy” rating on Thursday, December 15 by Jefferies. The stock has “Equal Weight” rating by Morgan Stanley on Friday, December 1. Jefferies maintained it with “Buy” rating and GBX 2990 target in Thursday, August 4 report. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, March 16. The stock of Hikma Pharmaceuticals PLC (LON:HIK) earned “Neutral” rating by JP Morgan on Thursday, March 16. The rating was maintained by JP Morgan with “Neutral” on Tuesday, June 27. See Hikma Pharmaceuticals PLC (LON:HIK) latest ratings:

31/05/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 1160.00 Maintain
21/05/2018 Broker: Barclays Capital Rating: Underweight Old Target: GBX 850.00 Maintain
18/05/2018 Broker: Jefferies Rating: Hold Old Target: GBX 997.00 Maintain
18/05/2018 Broker: Numis Securities Rating: Add Old Target: GBX 1300.00 New Target: GBX 1560.00 Downgrade
18/05/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 1160.00 Maintain
01/05/2018 Broker: Citigroup Rating: Buy Old Target: GBX 1250.00 New Target: GBX 1475.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 1160.00 Maintain
20/03/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 1180.00 New Target: GBX 1160.00 Maintain
19/03/2018 Broker: Barclays Capital Rating: Underweight Maintain
15/03/2018 Broker: Citigroup Rating: Buy New Target: GBX 1250.00 Upgrade

The stock of IntriCon Corporation (NASDAQ:IIN) hit a new 52-week high and has $48.07 target or 9.00% above today’s $44.10 share price. The 8 months bullish chart indicates low risk for the $307.13M company. The 1-year high was reported on Jun, 19 by If the $48.07 price target is reached, the company will be worth $27.64M more. It closed at $44.1 lastly. It is down 299.36% since June 19, 2017 and is uptrending. It has outperformed by 286.79% the S&P500. Some Historical IIN News: ; 23/05/2018 – IntriCon Presenting at Conference Tomorrow; 21/05/2018 – lntriCon Present at the 19th Annual B. Riley FBR Investor Conference; 09/04/2018 – IntriCon Closes Below 50-Day Moving Average: Technicals; 21/05/2018 – IntriCon Present at the 19th Annual B. Riley FBR Investor Conference; 16/03/2018 – IntriCon Closes Above 50-Day Moving Average: Technicals; 07/05/2018 – INTRICON CORP – ANTICIPATE SALES TO RANGE BETWEEN $105 MLN TO $108 MLN IN 2018; 13/03/2018 IntriCon Expands U.S. Manufacturing Footprint to Meet Rising Demand of Medical Business; 07/05/2018 – INTRICON CORP – ANTICIPATE 2018 SECOND-QUARTER NET SALES, TO RANGE BETWEEN $25.5 MLN AND $26.5 MLN; 21/05/2018 – IntriCon Presenting at Conference May 24; 07/05/2018 – IntriCon 1Q EPS 10c

Investors sentiment increased to 2.09 in Q1 2018. Its up 0.49, from 1.6 in 2017Q4. It is positive, as 2 investors sold IntriCon Corporation shares while 9 reduced holdings. 10 funds opened positions while 13 raised stakes. 2.78 million shares or 21.13% more from 2.29 million shares in 2017Q4 were reported. Navellier And Inc has invested 0.04% in IntriCon Corporation (NASDAQ:IIN). S Squared Technology Ltd Liability, New York-based fund reported 27,706 shares. Eam Limited Liability Company reported 89,883 shares. Morgan Stanley has invested 0% in IntriCon Corporation (NASDAQ:IIN). Kopp Investment Advisors Ltd Limited Liability Company reported 0.3% stake. Gamco Inc Et Al accumulated 17,900 shares. Mairs And Power Inc, Minnesota-based fund reported 109,400 shares. Bard Assocs Inc holds 0.36% or 36,400 shares. 127,500 were accumulated by Bridgeway Management. Northern Tru reported 0% in IntriCon Corporation (NASDAQ:IIN). Federated Invsts Inc Pa reported 0% in IntriCon Corporation (NASDAQ:IIN). Thompson Davis Incorporated owns 0.04% invested in IntriCon Corporation (NASDAQ:IIN) for 750 shares. Acadian Asset Mgmt Ltd Liability Company owns 35,874 shares. White Pine Ltd Company has 57,205 shares for 0.43% of their portfolio. Hillsdale Invest Management stated it has 0.05% in IntriCon Corporation (NASDAQ:IIN).

Among 5 analysts covering IntriCon (NASDAQ:IIN), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. IntriCon had 7 analyst reports since September 22, 2015 according to SRatingsIntel. On Wednesday, April 11 the stock rating was initiated by FBR Capital with “Buy”. The firm has “Neutral” rating given on Friday, August 25 by Longbow. FBR Capital maintained IntriCon Corporation (NASDAQ:IIN) rating on Wednesday, June 13. FBR Capital has “Buy” rating and $45 target. Dougherty & Company maintained the shares of IIN in report on Friday, February 17 with “Buy” rating. As per Wednesday, May 9, the company rating was maintained by FBR Capital. Zacks downgraded the stock to “Sell” rating in Tuesday, September 22 report.

More notable recent IntriCon Corporation (NASDAQ:IIN) news were published by: which released: “Mid-Day Market Update: Pivotal Software Gains Following Q1 Results; Flex Pharma Shares Slide” on June 13, 2018, also with their article: “Intricon Corp (IIN) PT Raised to $45 at B.Riley/FBR” published on June 13, 2018, published: “38 Biggest Movers From Yesterday” on June 14, 2018. More interesting news about IntriCon Corporation (NASDAQ:IIN) were released by: and their article: “31 Stocks Moving In Wednesday’s Mid-Day Session” published on June 13, 2018 as well as‘s news article titled: “IntriCon Present at the 19th Annual B. Riley FBR Investor Conference” with publication date: May 21, 2018.

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, makes, and distributes body-worn devices in the United States, Europe, Asia, and internationally. The company has market cap of $307.13 million. The firm operates in two divisions, Body Worn Devices and Hearing Health Direct-To-Consumer. It has a 115.75 P/E ratio. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for bio-telemetry devices, hearing instruments, and professional audio communication devices.

Analysts await IntriCon Corporation (NASDAQ:IIN) to report earnings on August, 1. They expect $0.10 earnings per share, up 25.00% or $0.02 from last year’s $0.08 per share. IIN’s profit will be $696,447 for 110.25 P/E if the $0.10 EPS becomes a reality. After $0.10 actual earnings per share reported by IntriCon Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

The stock increased 1.26% or GBX 17.5 during the last trading session, reaching GBX 1409. About 170,973 shares traded. Hikma Pharmaceuticals PLC (LON:HIK) has 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

Hikma Pharmaceuticals PLC develops, makes, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. The company has market cap of 3.40 billion GBP. It operates through three divisions: Branded, Injectables, and Generic. It currently has negative earnings. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system , gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.

IntriCon Corporation (NASDAQ:IIN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *